Biopac Systems, Inc.

Biopac Systems, Inc., a for-profit Subchapter S corporation manufacturer of biomedical research equipment and data acquisition systems headquartered in Goleta, California, sells physiological monitoring devices, wireless sensors, and specialized recording systems to federal research institutions and medical facilities as a prime contractor on 100% of its recent awards. The company competes full-and-open (no set-aside designations on the vast majority of its footprint) and holds primary NAICS classifications under Electromedical and Electrotherapeutic Apparatus Manufacturing (334510) and Analytical Laboratory Instrument Manufacturing, with work spanning medical device procurement (PSC codes 6515 and 6520).

Biopac's customer base is highly fragmented across fifty-six federal agencies with shallow penetration at each. The top five customer agencies by award count (Department of the Army Medical Command, Department of the Navy Bureau of Medicine and Surgery, VA VISN 1, VA VISN 21, and the National Institute on Drug Abuse) account for only 25% of recent awards. By potential dollar value, the concentration is similarly dispersed: Army Medical Command leads with $302 thousand across seventeen awards, followed by VA VISN 22 ($237 thousand), VA VISN 2 ($236 thousand), VA VISN 4 ($201 thousand), and Army Materiel Command RDECOM ($176 thousand). Two hundred nineteen awards across recent years have generated $3.9 million in combined potential value and $6.7 million in obligated dollars, indicating substantial carryover from prior-year awards. The company operates exclusively as a prime contractor; a single sub-award to Leidos for research support services completed in 2026 accounts for all subcontract exposure.

Representative contract work includes an $77,793 firm fixed-price purchase order from the Army Research Laboratory for an MP200 data acquisition system with AcqKnowledge license (August 2025), a $34,424 order from VA VISN 2 (James J. Peters VAMC Bronx) for an MP160 system supporting psychophysiology research on veteran suicide risk (September 2024), a $25 thousand NIDA award for a physiological measurement system supporting ecological momentary assessment and just-in-time adaptive intervention studies (July 2025), and a $24,991 National Institute on Alcohol Abuse and Alcoholism order for wireless in vivo sensors (August 2025). Smaller orders dominate the portfolio: a $4,800 Navy Bureau of Medicine and Surgery purchase order for an NSMRL AcqKnowledge perpetual software license (May 2026), a $17,209 National Institute of Neurological Disorders and Stroke award for an MRI-compatible physiological monitoring device (July 2024), and a $13,176 National Heart, Lung, and Blood Institute small-business-set-aside order for a cardiac bioimpedance system (May 2024). Biopac also holds a federal grant as recipient: a National Institute of Mental Health SBIR project grant awarded September 2023 with completion targeted July 2027 for development of a temperature-controlled wireless recording system for immature rodent EEG and physiological research, conducted in collaboration with the University of Utah.

Biopac participates in one parent vehicle: the One Acquisition Solution for Integrated Services (OASIS) multi-agency IDIQ, with one recorded task order. Award volume has declined sharply—ten awards in 2022, twelve in 2023, four in 2024, four in 2025, and one in 2026—indicating contraction or longer order cycles. Only one award faces completion within the next twenty-four months, limiting near-term recompete exposure. The company's footprint reflects its positioning as a specialized biomedical equipment manufacturer serving NIH institutes (NIDA, NINDS, NHLBI, NIAAA, NIMH), Veterans Affairs research networks across multiple VISNs, Army research facilities, and Navy technical commands, primarily through transactional purchase orders for off-the-shelf physiological monitoring and data acquisition products rather than through large or multi-year contracts.

Data Acquisition Equipment